Electra raises $350m in IPO as shares slip on Nasdaq debut - The Pharma Letter
Why now
Thesis: Biotech IPO slipping on debut signals weak risk appetite
Catalyst to watch: Subsequent IPO performance
Main risk: New-issue demand may deteriorate further
Why it matters
A biotech IPO pricing then slipping on debut signals weak risk appetite for new issues.
Related assets & topics
Nasdaq Composite · ^IXICHealthcareiShares Biotech ETF · IBBSPDR Biotech ETF · XBISources
- googlenews · news.google.com · 2026-09-21 11:40 UTC